Related Experiment Video
Updated: Jun 14, 2026
11:04
An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
Photodynamic Therapy with Verteporfin for Corneal Neovascularisation
Summary
Photodynamic therapy effectively treated corneal neovascularization and associated lipid keratopathy in a patient. This treatment prevented recurrence and progression of the condition without significant side effects.
Area of Science:
- Ophthalmology
- Medical Treatments
Background:
- Corneal neovascularization presents significant therapeutic challenges.
- Lipid keratopathy can be a secondary complication of corneal neovascularization.
Purpose of the Study:
- To evaluate the efficacy of photodynamic therapy in managing corneal neovascularization with secondary lipid keratopathy.
Main Methods:
- Photodynamic therapy utilizing Verteporfin was administered to a patient with corneal neovascularization and lipid keratopathy.
Main Results:
- The corneal neovascularization did not recur six months post-treatment.
- The size of the lipid keratopathy remained stable.
- No significant adverse effects were observed.
Conclusions:
- Photodynamic therapy with Verteporfin demonstrated utility as a treatment option.
- This modality offers a potential solution for corneal neovascularization and associated lipid keratopathy.
More Related Videos
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...